In8Bio, Inc. Stock Price, News & Analysis

IN8bio, Inc. (Nasdaq: INAB) reported encouraging results for its Phase 1 clinical trials of INB-100 and INB-200, focusing on leukemia and glioblastoma patients. At the EBMT Annual Meeting, all three INB-100 patients were in complete remission, with durable remissions between 9 to 23 months. INB-200 showed a manageable safety profile with no dose-limiting toxicities. Financially, cash decreased to $32.1 million, and R&D expenses rose to $2.4 million. The company experienced a net loss of $6.1 million for Q1 2022, compared to a loss of $3.1 million in Q1 2021.

IN8bio, Inc. (Nasdaq: INAB) announced the launch of its new iPSC-based gamma-delta T cell platform, making it one of the few companies able to create both Vdelta1 and Vdelta2 T cell subtypes. This platform aims to facilitate the scaled manufacturing of 'off-the-shelf' cellular therapies. CEO William Ho highlighted this as a significant advancement, with plans to present data at the ASGCT Annual Meeting from May 16-19, 2022. The company is also set to discuss ongoing clinical trials and its product pipeline during a workshop on May 17, 2022.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical firm, announced its participation in several conferences in May 2022. Highlights include presentations at the ISCT International Society for Cell & Gene Therapy and the Allogeneic Cell Therapies Summit, featuring topics on innovative gamma-delta T cell therapies. Key speakers include CEO William Ho and COO Kate Rochlin. The company also focuses on the DeltEx platform for developing gamma-delta T cell therapies targeting solid tumors and leukemia. IN8bio is conducting Phase 1 trials for products INB-200 and INB-100.

IN8bio (Nasdaq: INAB) announced the appointment of Urvashi Patel, Ph.D., as Vice President of Regulatory Affairs and Stacey Bilinski as Vice President of Clinical Operations. These appointments aim to enhance the company's clinical pipeline, with plans to file at least one new IND this year. Dr. Patel brings over 17 years of drug development experience, including cell therapy, while Ms. Bilinski has over 30 years in clinical operations. IN8bio is focused on developing innovative gamma-delta T cell therapies for cancer treatment.

IN8bio, a clinical-stage biopharmaceutical company, announced its presentations for upcoming April conferences. At the AACR Annual Meeting 2022 in New Orleans, Dr. Lawrence Lamb will discuss γδ T cell-based therapy for gliomas on April 11, and Dr. Lei Ding will address drug-resistant immunotherapy on April 13. Additionally, CEO William Ho will participate in a panel at the BIO Alabama Annual Conference 2022 on April 25.

IN8bio specializes in developing gamma-delta T cell therapies for tumors and is currently running Phase 1 trials for INB-200 and INB-100.

IN8bio, Inc. (Nasdaq: INAB) shared promising results from its ongoing Phase 1 trial of INB-100 for treating patients with high-risk acute myeloid leukemia (AML). All three patients treated showed durable remissions lasting 23.3, 21.0, and 9.3 months post-bone marrow transplant (BMT). The immune systems of patients were effectively reconstituted at six months, with no serious treatment-related adverse events reported. This update was presented at the European Society for Blood and Marrow Transplantation (EBMT) 48th Annual Meeting, indicating potential for further clinical advancements.

IN8bio reported promising clinical results for INB-200 and INB-100, showing a well-tolerated safety profile and extended progression-free survival in glioblastoma and leukemia patients, respectively. The company raised $40 million through an IPO to fund development of its gamma-delta T cell therapies. Financially, it ended 2021 with $37 million in cash, up from $18 million in 2020. However, it also faced a net loss of $14.7 million for the year. As the company continues to advance its clinical programs, it plans to file an IND for INB-400 and present at several upcoming scientific conferences.

IN8bio, Inc. (Nasdaq: INAB) announced its participation in several upcoming virtual and hybrid conferences in March 2022. Key events include the European Society for Medical Oncology Congress on March 7-8, featuring a presentation on engineered γδ T-cells, and the Cowen 42nd Annual Health Care Conference on March 7, where CEO William Ho will discuss the company overview. Additional presentations will take place at the Oppenheimer Healthcare Conference and the European Society for Blood and Marrow Transplantation meeting.

IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company focused on gamma-delta T cell therapies, announced executive presentations at two upcoming events. The BIO CEO & Investor Conference will take place from February 14-17, 2022, featuring CEO Will Ho. Additionally, at the Next Generation CAR-TCR Summit in London on February 22-24, 2022, CSO Dr. Lawrence Lamb and COO Dr. Kate Rochlin will present relevant research on CAR-T cell therapies. IN8bio is advancing clinical trials for its lead products targeting glioblastoma and leukemia.